People · Operator
Named in public records as an officer, director or promoter · active 2018–2018 · Biotech
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Transplant Genomics Inc. | — | Biotech | Series A | $20.6M | $288.4M | 2018 |
David Kravitz at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside David Kravitz on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Jay Venkatesan | 1 | 5 |
| Stanley Rose | 1 | 4 |
| Peter Lewis | 1 | 4 |
| Darren Lee | 1 | 3 |
| DANIEL SOLOMON | 1 | 3 |
| Roy First | 1 | 1 |
| Brett Jensen | 1 | 1 |
| Chris O'Connor | 1 | 1 |
| Daniel Salomon | 1 | 1 |
| Michael Abecassis | 1 | 1 |
| Kyle Hart | 1 | 1 |
| Dierdre Pierry | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.